Skip to content
Find a Provider
Frank C. Passero, M.D.

Frank C. Passero, M.D.

Hematology & Oncology , Cancer

5 out of 5 stars
371 Ratings
42 Comments
UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 275-5863

About Me

As a physician I aim to provide patients with an understanding of their medical condition and guidance as they navigate complex medical decisions. I consider honesty, compassion and my medical knowledge as foundational principles upon which I seek to build a trusting patient-physician relationship. ...
As a physician I aim to provide patients with an understanding of their medical condition and guidance as they navigate complex medical decisions. I consider honesty, compassion and my medical knowledge as foundational principles upon which I seek to build a trusting patient-physician relationship. Getting to know my patients, their unique circumstances and goals is a key aspect of my practice, in order to provide patients with a personalized plan of care.

I obtained my medical degree from Jefferson Medical College in Philadelphia, Pennsylvania and went on to complete internship, residency, and a chief medical residency in Internal Medicine at Scripps Mercy Hospital in San Diego. I pursued my Hematology and Oncology fellowship training at Tufts Medical Center in Boston, Massachusetts where I carried out laboratory research studying the effects of proteasome and HDAC inhibitors in lymphoma.

I have a special interest in plasma cell disorders including myeloma and amyloidosis, and would like to provide patients with the opportunity to participate in well-designed clinical trials for these and other related diseases.

Certified Specialties

Hematology - American Board of Internal Medicine

Internal Medicine - American Board of Internal Medicine

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, Tufts Medical Center. 2014 - 2017

Residency, Internal Medicine, Mercy Hospital & Medical Center-San Diego (GME). 2011 - 2014

Internship, Internal Medicine, Mercy Hospital & Medical Center-San Diego (GME). 2010 - 2011

Education

MD | Thomas Jefferson University Hospital. 2010

Research

Clinical Trials

CMMY18034: S1702, A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated Amyloid Light Chain Amyloidosis

Lead Researcher: Frank C Passero

All participants will receive the same study drug. If you decide to participate, you will receive up to 24 cycles (1 cycles = 28 days) of the study drug, isatuximab, as an outpatient (meaning you will not be admitted to the hospital to receive study ...

All participants will receive the same study drug. If you decide to participate, you will receive up to 24 cycles (1 cycles = 28 days) of the study drug, isatuximab, as an outpatient (meaning you will not be admitted to the hospital to receive study drug. During the first cycle (or 28 days), you will receive isatuximab on Day 1, 8, 15 and 22 by intravenous (IV) infusion (into your vein). For all other cycles (Cycle 2, up to Cycle 24), you will receive isatuximab on Days 1 and 15.

IMMY17131: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Lead Researcher: Frank C Passero

There are two treatment groups in this study. The study medication will be given in treatment cycles, and each cycle is 28 days long. Group A: Cyclophosphamide, bortezomib (VELCADE®) and dexamethasone (CyBorD). Group B: Daratumumab plus cyclophospham...

There are two treatment groups in this study. The study medication will be given in treatment cycles, and each cycle is 28 days long. Group A: Cyclophosphamide, bortezomib (VELCADE®) and dexamethasone (CyBorD). Group B: Daratumumab plus cyclophosphamide, bortezomib (VELCADE®) and dexamethasone (CyBorD)

Publications

Journal Articles

A Rare Case of Renal Thrombotic Microangiopathy and Focal Segmental Glomerulosclerosis Secondary to Plasma Cell Leukemia.

Komisarof J, Forman J, Goldman B, Syposs C, Passero F, Garbade E

Case reports in hematology.. 2023 2023 :7803704. Epub 02/18/2023.

Light chain deposition disease masquerading as smoking-associated nodular glomerulosclerosis with deposits identified by electron microscopy only.

Alom MS, Grewal R, Passero FC, Goldman B, Choung HYG

CEN case reports.. 2022 November 11 (4):448-452. Epub 03/22/2022.

An Unusual Case of Multiple Myeloma with Light-Chain Cast Nephropathy Secondary to a Very Large Plasmacytoma without Bone Marrow Involvement.

Komisarof J, Lipof J, DiTursi J, Chowdhry A, Grace Choung HY, Burack WR, Constine L, Passero F

Case reports in hematology.. 2022 2022 :7531142. Epub 02/21/2022.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL,

The New England journal of medicine.. 2021 July 1385 (1):46-58. Epub 1900 01 01.

Oncogenic Integration of Nucleotide Metabolism Fatty Acid Synthase in Non-Hodgkin Lymphoma.

Ravi D, Beheshti A, Abermil N, Lansigan F, Kinlaw W, Matthan NR, Mokhtar M, Passero FC, Puliti P, David KA, Dolnikowski GG, Su X, Chen Y, Bijan M, Varshney RR, Kim B, Dave SS, Rudolph MC, Evens AM

Frontiers in oncology.. 2021 11 :725137. Epub 10/26/2021.

Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.

Evens AM, Konry T, David K, Mokhtar M, Chen Y, Beheshti A, Passero F, Purvey S, Sarkar S, Ravi D

Leukemia.. 2020 May 34 (5):1291-1304. Epub 11/26/2019.

Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.

Evens AM, David KA, Beheshti A, McDonald JT, Ravi D, Passero FC

British journal of haematology.. 2020 January 188 (2):295-308. Epub 08/26/2019.

A review of thrombotic microangiopathies in multiple myeloma.

Lipe B, Passero FC, Gleber C, Portuguese AJ

Leukemia research.. 2019 October 85 :106195. Epub 07/29/2019.

Second line treatment options for pancreatic cancer.

Saif MW, Passero FC

Expert opinion on pharmacotherapy.. 2017 October 18 (15):1607-1617. Epub 10/06/2017.

The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.

Passero FC, Grapsa D, Syrigos KN, Saif MW

Expert review of anticancer therapy.. 2016 July 16 (7):697-703. Epub 06/03/2016.

Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.

Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar A, Gartenhaus RB, Evens AM

Cancer research.. 2016 June 176 (11):3319-31. Epub 03/17/2016.

Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology.

Abrams MJ, Rakszawski K, Vasekar M, Passero F, Abbas A, Jia Y, Saif MW

Therapeutic advances in gastroenterology.. 2016 March 9 (2):141-51. Epub 1900 01 01.

Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015).

Passero FC, Saif MW

JOP : Journal of the pancreas.. 2015 March 2016 (2):99-103. Epub 03/20/2015.

Otic mesenchyme expression of Cre recombinase directed by the inner ear enhancer of the Brn4/Pou3f4 gene.

Ahn KJ, Passero F, Crenshaw EB

Genesis : the journal of genetics and development.. 2009 March 47 (3):137-41. Epub 1900 01 01.

Mexiletine for refractory chronic daily headache: a report of nine cases.

Marmura MJ, Passero FC, Young WB

Headache.. 2008 48 (10):1506-10. Epub 09/12/2008.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.9 stars

Likelihood of recommending this care provider to others

5.0 stars

Explanations the care provider gave you about your problem or condition

4.9 stars

Care provider's efforts to include you in decisions about your care

4.9 stars

Concern the care provider showed for your questions or worries

4.9 stars

Patient Comments

5.0 stars

Shown respect and understanding

Jan 31, 2025

5.0 stars

I find Dr. Passero to be extremely empathetic and in tune with my specific concerns as a musician.

Jan 02, 2025

5.0 stars

Dr Biglow and Dr. Passero were both very helpful and very informative

Dec 16, 2024

5.0 stars

Dr Passero listened to my experience on Revlimid. He made the decision to stop the medication and suggested an alternative plan. He was aware of my past history on this medication and recommended an alternative plan to meet my needs.

Nov 05, 2024

5.0 stars

I'm very thankful for the level of support, respect and knowledge I get from the team at UR

Nov 02, 2024

5.0 stars

Just Amazing how happy I was with my appointment.

Oct 08, 2024

5.0 stars

Amy Quinlan is the best she listened to all of my concerns and answered all of my questions. She answers all of my messages in a timely manner. Frank Passero, MD and Omar Aljitawi, MBBS are great too very helpful and really make me feel they care.

Aug 19, 2024

5.0 stars

Excellent

Apr 24, 2024

4.6 stars

I had no problems with the care provider [...].

Apr 22, 2024

5.0 stars

Dr. Passero is the absolute best. He is very knowledgeable and caring. You don't come across too many Dr's like him.

Apr 04, 2024